The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Improvement of migraine symptoms with a proprietary supplement containing riboflavin, magnesium and Q10: a randomized, placebo-controlled, double-blind, multicenter trial
Open accessAbstract
BACKGROUND: Non-medical, non-pharmacological and pharmacological treatments are recommended for the prevention of migraine. The purpose of this randomized double-blind placebo controlled, multicenter trial was to evaluate the efficacy of a proprietary nutritional supplement containing a fixed combination of magnesium, riboflavin and Q10 as prophylactic treatment for migraine. METHODS: 130 adult migraineurs (age 18 - 65 years) with ≥ three migraine attacks per month were randomized into two treatment groups: dietary supplementation or placebo in a double-blind fashion. The treatment period was 3 months following a 4 week baseline period without prophylactic treatment. Patients were assessed before randomization and at the end of the 3-month-treatment-phase for days with migraine, migraine pain, burden of disease (HIT-6) and subjective evaluation of efficacy. RESULTS: Migraine days per month declined from 6.2 days during the baseline period to 4.4 days at the end of the treatment with the supplement and from 6.2.days to 5.2 days in the placebo group (p = 0.23 compared to placebo). The intensity of migraine pain was significantly reduced in the supplement group compared to placebo (p = 0.03). The sum score of the HIT-6 questionnaire was reduced by 4.8 points from 61.9 to 57.1 compared to 2 points in the placebo-group (p = 0.01). The evaluation of efficacy by the patient was better in the supplementation group compared to placebo (p = 0.01). CONCLUSIONS: Treatment with a proprietary supplement containing magnesium, riboflavin and Q10 (Migravent® in Germany, Dolovent® in USA) had an impact on migraine frequency which showed a trend towards statistical significance. Migraine symptoms and burden of disease, however, were statistically significantly reduced compared to placebo in patients with migraine attacks.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Olesen, J. (2004) · Cephalalgia · doi:10.1111/j.1468-2982.2003.00824.x · Cited by 2,056
A six-item short-form survey for measuring headache impact: The HIT-6™
Kosinski, M., Bayliss, M. S., Bjorner, J. B., Ware, J. E., Garber, W. H., Batenhorst, A., Cady, R., Dahlöf, C. G. H., Dowson, A., & Tepper, S. (2003) · Quality of Life Research · doi:10.1023/a:1026119331193 · Cited by 1,376
Cited by
Magnesium in Prevention and Therapy
Gröber, U., Schmidt, J., & Kisters, K. (2015) · Nutrients · doi:10.3390/nu7095388 · Cited by 1,061
Riboflavin: The Health Benefits of a Forgotten Natural Vitamin
Suwannasom, N., Kao, I., Pruß, A., Georgieva, R., & Bäumler, H. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21030950 · Cited by 444
The metabolic face of migraine — from pathophysiology to treatment
Gross, E. C., Lisicki, M., Fischer, D., Sándor, P. S., & Schoenen, J. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-019-0255-4 · Cited by 262
Prophylaxis of migraine headaches with riboflavin: A systematic review
Thompson, D. F., & Saluja, H. S. (2017) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.12548 · Cited by 101
de Roos, N. M., van Hemert, S., Rovers, J. M. P., Smits, M. G., & Witteman, B. J. M. (2017) · European Journal of Clinical Nutrition · doi:10.1038/ejcn.2017.57 · Cited by 89
Metadata
- Authors
- on behalf of the Migravent® Study Group, Gaul, C., Diener, H.-C., & Danesch, U.
- Venue
- The Journal of Headache and Pain
- Published
- 2015-04-03
- Volume
- 16
- Issue
- 1
- Pages
- 516-516
- ISSN
- 1129-2369 (ISSN-L)
- 1129-2377
- OpenAlex
- W2003839529
- Cited by
- 170
- References
- 2
- FWCI
- 10.85
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Improvement of migraine symptoms with a proprietary supplement containing riboflavin, magnesium and Q10: a randomized, placebo-controlled, double-blind, multicenter trial. https://app.cochat.ai/papers/10.1186/s10194-015-0516-6
- The paper
- on behalf of the Migravent® Study Group, Gaul, C., Diener, H.-C., & Danesch, U. (2015). Improvement of migraine symptoms with a proprietary supplement containing riboflavin, magnesium and Q10: a randomized, placebo-controlled, double-blind, multicenter trial. The Journal of Headache and Pain. https://doi.org/10.1186/s10194-015-0516-6
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.